Octreotide vs Thymosin Alpha-1
Overview
Octreotide is primarily a hormonal peptide, while Thymosin Alpha-1 is used for healing & recovery.
This page compares Octreotide and Thymosin Alpha-1 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Octreotide | Thymosin Alpha-1 | |
|---|---|---|
| Category | Hormonal | Healing & Recovery |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) | 1.6-3.2 mg |
| Frequency | Every 4 weeks (LAR); two to four times daily (immediate-release) | twice-weekly |
| Reported benefits | Reduction of growth hormone and IGF-1 in acromegaly, suppression of carcinoid flushing and diarrhea, control of VIPoma-associated watery diarrhea, antiproliferative effect on low-grade neuroendocrine tumors, reduction of urinary 5-HIAA biomarkers | Immune enhancement, antiviral properties, chronic infection support, cancer therapy adjunct |
| Reported side effects | Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain | Well-tolerated. Rare: injection site reactions, mild flu-like symptoms |
Key differences
Primary use. Octreotide is categorised under Hormonal, while Thymosin Alpha-1 falls under Healing & Recovery. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Octreotide: FDA-approved. Thymosin Alpha-1: not FDA-approved; treated as a research compound.
Dosing. Octreotide is typically dosed at 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)). Thymosin Alpha-1 is typically dosed at 1.6-3.2 mg (twice-weekly).
Can you stack them?
Some protocols combine peptides, but stacking Octreotide and Thymosin Alpha-1 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Octreotide and Thymosin Alpha-1?
- Octreotide is primarily a hormonal peptide, while Thymosin Alpha-1 is used for healing & recovery. Octreotide is FDA-approved for one or more indications, whereas Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
- What is Octreotide used for?
- FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988.
- What is Thymosin Alpha-1 used for?
- Immune system support.
- Can you take Octreotide and Thymosin Alpha-1 together?
- Some users combine peptides within a single protocol, but stacking Octreotide and Thymosin Alpha-1 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Octreotide or Thymosin Alpha-1 FDA-approved?
- Octreotide is FDA-approved for one or more indications. Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
Read the full articles
- Octreotide — full monograph: mechanism, research, dosing & references
- Thymosin Alpha-1 — full monograph: mechanism, research, dosing & references